CPIX closes $100 million Apotex sale, declares $1.50 special dividend as Cumberland shifts to development stage
A $100 million cash transaction with Apotex Health, the largest Canadian pharmaceutical company, closed July 1, 2026, transferring Cumberland Pharmaceuticals' (Nasdaq: CPIX) full portfolio of FDA-approved brands and related commercial organization to the buyer. The deal carried an additional $11 million in inventory and transition-services funding. Cumberland's board followed the close with a $1.50 per share special cash dividend, paid July 31 to shareholders of record as of July 23.
Key takeaways
- Cumberland Pharmaceuticals (Nasdaq: CPIX) closed a $100 million cash sale of its FDA-approved branded drug portfolio and commercial organization to Apotex Health on July 1, 2026, plus an additional $11 million for inventory and transition services.
- Cumberland's board declared a $1.50 per share special cash dividend, paid July 31, 2026, to shareholders of record as of July 23, 2026.
- The transaction was unanimously approved by the board and backed by more than 99% of shareholder votes cast, with Cumberland retaining its development pipeline and majority ownership in Cumberland Emerging Technologies.
- For Q2 2026, Cumberland reported a $3.1 million loss from continuing operations and a $4.1 million net loss, with total assets of about $63 million and $4 million in cash as of June 30, 2026.
- Cumberland retains four Phase 2 clinical programs, led by ifetroban, which showed encouraging results in trials for Duchenne muscular dystrophy-associated cardiomyopathy and cancer metastasis prevention.
A $100 million cash transaction with Apotex Health, the largest Canadian pharmaceutical company, closed July 1, 2026, transferring Cumberland Pharmaceuticals' (Nasdaq: CPIX) full portfolio of FDA-approved brands and related commercial organization to the buyer. The deal carried an additional $11 million in inventory and transition-services funding. Cumberland's board followed the close with a $1.50 per share special cash dividend, paid July 31 to shareholders of record as of July 23.
Transaction mechanics and capital return
The deal received unanimous approval from Cumberland's board before proceeding to shareholders, where more than 99% of votes cast favored the transaction. Under the agreement, Apotex absorbed Cumberland's branded drug portfolio and commercial infrastructure. Cumberland retains its development pipeline and majority ownership in Cumberland Emerging Technologies.
The special dividend came out of a post-close financial review. Cumberland's tax advisors, analyzing refined financial projections, identified greater net cash from the transaction than originally projected. The board evaluated the surplus and available alternatives before landing on the $1.50 payout. CEO A.J. Kazimi characterized the transaction as unlocking substantial value for shareholders while positioning Cumberland for its next phase as an innovation-focused biopharmaceutical organization.
Q2 financials: a transitional print
The second quarter income statement reflects the reorganization. Cumberland reclassified revenues and expenses tied to the Apotex transaction as discontinued operations, leaving a loss from continuing operations of $3.1 million for the quarter. Including discontinued operations, the net loss was $4.1 million.
At June 30, 2026, total assets stood at approximately $63 million, with $4 million in cash and cash equivalents. Liabilities were $46 million; shareholders' equity was $17 million. Cumberland also retired its bank line of credit through a $5.2 million payment at quarter-end.
Pipeline data and what to watch
Four Phase 2 clinical programs remain with the company. The most recently discussed is ifetroban. Updated results from the Phase 2 FIGHT DMD trial in Duchenne muscular dystrophy-associated cardiomyopathy were presented at the PPMD Conference in June 2026, showing blood biomarker findings described as directionally consistent with heart muscle protection.
Vanderbilt Health and Cumberland also reported results from a randomized, placebo-controlled Phase 2 study evaluating ifetroban in cancer metastasis prevention among Stage I to III solid tumor patients at high risk of recurrence. The trial met its primary endpoint of safety and feasibility. On the prespecified secondary endpoint, metastatic recurrence at 12 months was 17% in the ifetroban arm (3 of 18 patients) versus 50% in the placebo arm (5 of 10 patients), an odds ratio of 0.21 (p=0.09, not statistically significant). Deaths from distant metastatic disease: none among 18 ifetroban-treated patients versus 3 of 10 in the placebo group (p=0.037).
An earnings call covering these results is scheduled for 4:30 p.m. Eastern on August 4, 2026.
Related reading
Filed by the newsroom of MarketPR on August 4, 2026. Source: sec.gov. Indicative figures are not investment advice.